Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-B + Raltegravir in ATLL
NCT01000285Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2010
- Primary completion
- May 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and raltegravir in adult T-cell leukemia-lymphoma (ATLL), sponsored by Washington University School of Medicine. Primary endpoints: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events and Best Overall Response. Started Sep 2010; status: completed.
02
Drugs
bortezomibraltegravir
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT01000285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000285.